Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) from Overweight to Neutral, as per analyst Josh Schimmer.
September 23, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer downgraded 4D Molecular Therapeutics from Overweight to Neutral, indicating a less optimistic outlook on the stock.
The downgrade from Overweight to Neutral by a reputable analyst suggests a shift in sentiment, which could lead to a short-term negative impact on FDMT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100